Evidence map›Paper›PMID 30816484›Full record

ArticleMolecular medicine reports2019

Effects of tyrosol and farnesol on Candida albicans biofilm.

Sarra Sebaa, Zahia Boucherit-Otmani, Philippe Courtois

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 60 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. The effects of tyrosol on yeasts: an overview of current knowledge.Applied microbiology and biotechnology · 2025
    Review
  5. Cyclodextrins in action: ModulatingBiotechnology reports (Amsterdam, Netherlands) · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Microorganisms · 2023
    Review
  16. Candida albicans antibiofilm molecules: analysis based on inhibition and eradication studies.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023
    Review
  17. Mycotoxins fromMycology · 2023
    Article
  18. Review
  19. Rapid Synergistic Biofilm Production ofInternational journal of molecular sciences · 2022
    Article
  20. In vitro antibiofilm efficacy of farnesol against Candida species.International microbiology : the official journal of the Spanish Society for Microbiology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Sarra SebaaLaboratory of Physiology and Pharmacology, Université Libre de Bruxelles, B‑1070 Brussels, Belgium.
Zahia Boucherit-OtmaniLaboratory of Antibiotics and Antifungals, Physico‑Chemistry, Synthesis and Biological Activity, University of Tlemcen, 13000 Tlemcen, Algeria.
Philippe CourtoisLaboratory of Physiology and Pharmacology, Université Libre de Bruxelles, B‑1070 Brussels, Belgium.
Université Libre de Bruxelles · BEUniversity of Abou Bekr Belkaïd · DZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present in vitro study examined the effects of the quorum‑sensing molecules farnesol and tyrosol on the development of Candida albicans biofilm in order to elucidate their role as novel adjuvants in oral hygiene. The investigation was conducted in C. albicans ATCC 10231 and C. albicans isolates from dentures and was performed in flat‑bottomed 96‑well polystyrene plates. Yeast growth and their capacity to form biofilms were evaluated following 24 and 48 h incubations at 37˚C in Sabouraud broth supplemented with 0.001‑3 mM farnesol and/or 1‑20 mM tyrosol. Yeast growth was assessed by turbidimetry and biofilms were quantitated by crystal violet staining, under aerobic and anaerobic conditions. The viability of the fungal cells was controlled by the culture of planktonic cells and by examination of the biofilms using fluorescence microscopy following staining with fluorescein diacetate and ethidium bromide. Farnesol at 3 mM exerted a stronger action when added at the beginning of biofilm formation (>50% inhibition) than when added to preformed biofilms (<10% inhibition). Similarly, tyrosol at 20 mM had a greater effect on biofilm formation (>80% inhibition) than on preformed biofilms (<40% inhibition). Despite significant reductions in attached biomass, yeast growth varied little in the presence of the investigated molecules, as corroborated by the turbidimetry, culture of supernatants on solid culture medium followed by counting of colony‑forming units and viability tests using fluorescence microscopy. At the highest tested concentration, the molecules had a greater effect during the initial phases of biofilm formation. The effect of farnesol during anaerobiosis was not significantly different from that observed during aerobiosis, unlike that of tyrosol during anaerobiosis, which exhibited slightly reduced yeast biofilm inhibition. In conclusion, the present study demonstrated the specific anti‑biofilm effect, independent of fungicidal or fungistatic action, of farnesol and tyrosol, as tested in C. albicans ATCC 10231 and 6 strains isolated from dentures. Prior to suggesting the use of these molecules for preventive purposes in oral hygiene, further studies are required in order to clarify the metabolic pathways and cellular mechanisms involved in their antibiofilm effect, as well as the repercussions on the oral microbiome.

Indexed as

BiofilmsCandida albicansFarnesolFluorescent Antibody TechniqueMicrobial ViabilityPhenylethyl AlcoholQuorum Sensing4-hydroxyphenylethanolFarnesolPhenylethyl Alcohol

Identifiers

PMID30816484
PMCPMC6423612
OpenAlexW2917605828

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.